UBS analyst Danielle Antalffy raised the firm’s price target on Inspire Medical (INSP) to $91 from $89 and keeps a Neutral rating on the shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire slides as ‘MAC flip flop’ adds uncertainty to coding saga, Truist says
- Inspire Medical Systems: Temporary MAC-CMS Reimbursement Misalignment Creates Overdone Pullback, Supporting Continued Buy Rating
- Inspire Medical falls -19.6%
- RBC says Inspire seeking clarity as reimbursement confusion drives stock down
- Two MACs remove CPT code 64568 for HGNS, says Piper Sandler